Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy
Open Access
- 6 October 2023
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-11
Abstract
Objectives: Pan-immune-inflammation value (PIV) is defined by the neutrophil, platelet, monocyte, and lymphocyte counts and is associated with immune-checkpoint inhibitor (ICI) therapy outcomes in advanced non-small cell lung cancer (aNSCLC). However, PIV is dynamic under therapy and its longitudinal assessment may help predict efficacy. This study investigated the impact of baseline PIV and its dynamics on ICI efficacy and its immune-related adverse events (irAEs). The study additionally attempted to understand the biological significance of PIV. Patients and methods: This retrospective study analyzed the clinical data of 269 consecutive patients with aNSCLC. PIV was calculated at baseline and at weeks 3–4 to determine its association with overall survival (OS), progression-free survival (PFS), and irAEs. Results: Results revealed that low baseline PIV was positively correlated with the incidence of irAEs. Moreover, a low PIV at baseline was significantly associated with a prolonged PFS (median PFS: 10 vs. 7 months, p = 0.0005) and OS (median OS: 29 vs. 21 months, p < 0.0001). When the PIV at baseline and weeks 3–4 was considered together, its low dynamics correlated with a higher incidence of irAEs (p = 0.001), a longer PFS (median PFS, 9 vs. 6 months, p = 0.012), and a longer OS (median OS; 28 vs. 21 months, p = 0.002). Conclusion: Thus, PIV at baseline and its dynamics are novel and potent predictors of irAEs, PFS, and OS in patients with aNSCLC receiving immunotherapy. Moreover, the PIV dynamics may be an effective, novel surrogate marker to dynamically observe the efficacy of immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (82273955, 82204504, 82273955, 82204504, 82273955, 82204504)
- Scientific research project of Jiangsu Provincial Health Commission (M2022080, M2022080, M2022080)
- Science and Technology Project of Nantong City (MS22021025, MS22022025, MS22021025, MS22022025, MS22021025, MS22022025)
- Multicenter Study Project of Affiliated Hospital of Nantong University (LCYJ-A10, LCYJ-A10, LCYJ-A10)
This publication has 47 references indexed in Scilit:
- Dynamic plasma microRNAs are biomarkers for prognosis and early detection of recurrence in colorectal cancerBritish Journal of Cancer, 2017
- Phenotype and function of tumor-associated neutrophils and their subsets in early-stage human lung cancerCancer Immunology, Immunotherapy, 2017
- Tumor-Associated Macrophages: Implications in Cancer ImmunotherapyImmunotherapy, 2017
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapyCancer Treatment Reviews, 2016
- Platelets in Tumor Progression: A Host Factor That Offers Multiple Potential Targets in the Treatment of CancerJournal of Cellular Physiology, 2014
- Modulation of neutrophil granulocytes in the tumor microenvironment: Mechanisms and consequences for tumor progressionSeminars in Cancer Biology, 2013
- Paraneoplastic Thrombocytosis in Ovarian CancerNew England Journal of Medicine, 2012
- The platelet contribution to cancer progressionJournal of Thrombosis and Haemostasis, 2011
- X-TileClinical Cancer Research, 2004
- Global cancer statisticsCA: A Cancer Journal for Clinicians, 1999